Heart Failure (HF) and cancer are the main causes of morbidity and mortality in developed countries [1], and their prevalence is increasing due to ageing of the population. Therefore, patients with both pathologies represent a challenge in our daily clinical practice [2]. Several cancer therapies have cardio-toxic effects and may increase de risk of developing HF in patients with malignancies [3]. Furthermore, a few recent studies have suggested that there could also be a relation between HF and cancer in the opposite direction, in other words, that patients with HF might be exposed to an increased risk of incident malignancies [4–9].
